Aktienanalyse zu DaVita Inc (DVA)DVADaVita Inc

DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company's robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company's international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company's U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

DaVita Inc is a good buy right now due to its current price of $187.31 being significantly lower than the analyst price targets, with Deutsche Bank's target at $265, indicating a potential upside of 41.5%. Additionally, the company reported a strong EPS of $4.02 in Q2, reflecting a 55% year-over-year increase, which suggests robust profitability and growth potential. The main risk is the insider selling trend, with Berkshire Hathaway reducing its holdings by 1.2 to 1.6 million shares, indicating some caution in the market.

13 analysts cover DVA: 3 rate it Buy, 8 Hold and 2 Sell. The average price target is 162.50.